TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01019681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood stem cell injection
Description: The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois).
Study: NCT01532687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT03911882

Intervention type: DIETARY_SUPPLEMENT
Intervention: Celergen Administration
Description: The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
Study: NCT01854125

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow mesenchymal stem cells transplantation
Description: Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow mesenchymal stem cells transplantation
Description: Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mesenchymal stem cells transplantation
Description: Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow msenchymal stem cells transplantation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow msenchymal stem cells transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow msenchymal stem cells transplantation
Study: NCT01532687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04070534

Intervention type: OTHER
Group type: OTHER
Intervention: PALS
Description: patient activated learning system
Study: NCT00896038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active placebo
Study: NCT01019109

Intervention type: DEVICE
Intervention: Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.
Description: PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.

Intervention type: DEVICE
Intervention: Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.
Description: PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
Study: NCT01532687

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT00807092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin dose must remain the same as that used prior to the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin dose must remain the same as that used prior to the trial.
Study: NCT03844191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: single subcutaneous administration of RUC-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: single subcutaneous administration of RUC-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: single subcutaneous administration of RUC-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: single subcutaneous administration of RUC-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: single subcutaneous administration of RUC-4
Study: NCT01788540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
Study: NCT01114841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam
Description: Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required.
Study: NCT02483247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
Study: NCT04476459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase.
Study: NCT02483247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg is administered once daily.
Study: NCT04488276

Intervention type: OTHER
Intervention: In-depth interviews
Description: In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.

Intervention type: OTHER
Intervention: In-depth interviews
Description: In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
Study: NCT02738775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03259867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injectable Product
Description: a PD-1 immune check inhibitor
Study: NCT02683759

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bio-enhanced Curcumin Soft Gelatin Capsule
Description: Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Aminosalicyclic acid
Description: Dosage is as instructed by patient's physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Aminosalicyclic acid
Description: Dosage is as instructed by patient's physician
Study: NCT02992899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaCore/electroCore non-invasive VNS device
Description: Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham gammaCore/electroCore
Description: Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: O-15 water
Description: Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
Study: NCT03259867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injectable Product
Description: a PD-1 immune check inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trans-arterial tirapazamine embolization
Description: Embolization with Lipiodol and Gelfoam

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trans-arterial tirapazamine embolization
Description: Embolization with Lipiodol and Gelfoam
Study: NCT02992899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-15 water
Description: Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
Study: NCT01590823

Intervention type: DRUG
Group type: OTHER
Intervention: Dabigatran Etexilate 110 mg
Description: All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
Study: NCT01284647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teprenone capsule and placebo of sucralfate
Description: Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucralfate and placebo of teprenone
Description: Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
Study: NCT01396616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental - Toric Intraocular lenses
Description: Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
Study: NCT04745143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of schizophrenia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator
Study: NCT02002767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velpatasvir
Description: Velpatasvir 100 mg (2 x 50 mg tablets) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
Study: NCT01339533

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation
Description: Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
Study: NCT04603430

Intervention type: OTHER
Intervention: Participation in a community wellness program
Description: Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.

Intervention type: OTHER
Intervention: Participation in a community wellness program
Description: Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
Study: NCT00966498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant
Description: Peripheral Blood Stem Cell Transplant